Sign In
Buy ASND
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
08:16pm, Thursday, 19'th Sep 2024
COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares (“A
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
04:04pm, Wednesday, 18'th Sep 2024
COPENHAGEN, Denmark, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has commenced an underwritten public offering of $300,000,000 of American Depositary
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
03:16pm, Tuesday, 17'th Sep 2024
ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.
Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?
10:06am, Tuesday, 17'th Sep 2024
Ascendis Pharma (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increa
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
12:18pm, Monday, 16'th Sep 2024
Ascendis Pharma A/S ASND released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature.
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
07:00am, Monday, 16'th Sep 2024
– TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p
COPENHAGEN, Denmark, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced initial data showing signs of clinical activity in heavily pre-treated patients with platinum
– U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in adults
Ascendis Pharma Takes A Big Price Cut On Skytrofa
01:30am, Thursday, 05'th Sep 2024
Shares of Ascendis Pharma are under pressure as the company posted a big Q2 revenue miss, driven by a decision to significantly reduce the net price of Skytrofa. Demand for Skytrofa remains strong and
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
05:02pm, Wednesday, 04'th Sep 2024
Tuesday, Ascendis Pharma A/S ASND reported second-quarter sales of $38.76 million (35.9 million euros), missing the consensus of $92.7 million, down from 47.4 million euros reported a year ago.
Why Ascendis Pharma Stock Tumbled by 11% Today
04:48pm, Wednesday, 04'th Sep 2024
The biotech released its second-quarter results and likely wishes it hadn't. It missed badly on the consensus analyst estimate for profitability.
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
09:09am, Wednesday, 04'th Sep 2024
Tuesday, Ascendis Pharma A/S ASND reported second-quarter sales of $38.76 million (35.9 million euros), missing the consensus of $92.7 million, down from 47.4 million euros reported a year ago.
Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript
09:41pm, Tuesday, 03'rd Sep 2024
Ascendis Pharma A/S (ASND) Q2 2024 Earnings Conference Call September 3, 2024 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Moller Mikkelsen - President & Chief Exe
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
05:06pm, Tuesday, 03'rd Sep 2024
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH® U.S. commercial launch, and general corporate purposes Proceeds to support
Ascendis Pharma Reports Second Quarter 2024 Financial Results
05:04pm, Tuesday, 03'rd Sep 2024
COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the second quarter ended June 30, 2024, and provided a business update.
